Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI

Enrollment has been completed in a Phase 2 study of ladostigil for the treatment of Alzheimer's Disease and results expected in Q4 2012